Engineered <i>Mycobacterium smegmatis</i> expressing anti-PD-L1/IL-15 immunocytokine induces and activates specific antitumor immunity
In summary, the engineered <i>M. smegmatis</i> can recruit and activate innate and adaptive antitumor immune responses, offering a potent cancer immunotherapy strategy to treat patients with cold tumors or resistance to checkpoint blockade.
Authors
- Junmeng Zhu
- Baorui Liu (ORCID: https://orcid.org/0000-0002-2539-7732)
- Jie Shen (ORCID: https://orcid.org/0000-0003-3157-4640)
- Xiaoxuan Sha
- Rutian Li (ORCID: https://orcid.org/0000-0003-4800-6156)
- Yi Mei (ORCID: https://orcid.org/0000-0003-0682-1363)
- Yang Yang (ORCID: https://orcid.org/0000-0002-2172-8477)
- Lin Li (ORCID: https://orcid.org/0000-0002-2158-7096)
- Jie Shao (ORCID: https://orcid.org/0000-0003-1222-0505)
- Fangcen Liu (ORCID: https://orcid.org/0000-0002-1845-9907)
Institutions
- Nanjing University of Chinese Medicine (CN)
- Nanjing Drum Tower Hospital (CN)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-05-01
- DOI
- https://doi.org/10.1136/jitc-2024-010118
- Citations
- 3
- Primary Topic
- Immune Cell Function and Interaction
- Type
- article
- Field-Weighted Citation Impact
- 2.39
Funders
- National Natural Science Foundation of China